Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940992 · ClinicalTrials.gov registry record · Phase 2
A Study of DER 45-EV Gel to Treat Rosacea
A Phase 2 study of Rosacea, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 10
- Study locations
NCT00940992 is a Phase 2 study of Rosacea that has completed, run by Sol-Gel Technologies. The registered enrollment target is 92 participants, below the 239-participant average among 23 other Rosacea trials with a reported enrollment target (62% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT00940992, a Phase 2 study of Rosacea, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 10
- Study locations
Study Summary
To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG DER 45 EV
Study Locations (10)
Florida
- Baumann Cosmetic & Research Institute - Miami
- FXM Research Corp - Miami
Texas
- DermResearch, Inc - Austin
- J & S Studies, Inc - College Station
Georgia
- Augusta Centre for Dermatology and Skin - Augusta
Minnesota
- Minnesota Clinical Study Center - Fridley
New York
- Skin Search of Rochester, Inc - Rochester
Tennessee
- Tennessee Clinical Research Center - Nashville
Washington
- Premier Clinical Research - Spokane
Wisconsin
- Madison Skin and Research, Inc - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00940992
The ClinicalTrials.gov registry entry for NCT00940992 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 23 other Rosacea trials with a reported enrollment target (62% lower). The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT00940992 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Florida, Texas, Georgia.
Frequently Asked Questions
What is clinical trial NCT00940992 about?
NCT00940992 is a clinical study titled "A Study of DER 45-EV Gel to Treat Rosacea". To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.
What is the current status of trial NCT00940992?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2012-01. Estimated completion is 2013-01.
What conditions does trial NCT00940992 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT00940992?
The interventions under investigation include: Vehicle (DRUG), DER 45 EV (DRUG).
Who is sponsoring clinical trial NCT00940992?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00940992 being conducted?
This trial has 10 study locations across Florida, Georgia, Minnesota, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
Rosacea and Ivermectin
COMPLETED · Phase 2
-
AGN-199201 for the Treatment of Erythema With Rosacea
COMPLETED · Phase 2
-
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 2
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.